Reports published from the prospective follow-up study of ZZ and SZ individuals up to age 26 years, focusing on clinical health, lung and liver function tests and plasma markers of the protease/protease inhibitor balance, have shown that ZZ and SZ subjects had significantly higher plasma concentrations of α2-MG, ACT and antithrombin III [20] at age 8 and 18 compared with MM control subjects. This evidence concerns the gene SERPINC1 and Miyoshi myopathy.